Perspective on the development of a bioengineered patch to treat heart failure: rationale and proposed design of phase I clinical trial

Abstract

This perspective focuses on the development of tissue engineered (TE) cell-based therapies to treat left ventricular (LV) dysfunction and chronic heart failure (CHF). The development of induced pluripotent stem cells enabled investigators to seed or co-culture human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) alone and in combination with other cells onto bioengineered scaffolds applied to the epicardial surface of the damaged left ventricle. Using our work as an example, we show how a xenograft implant of a bioengineered scaffold embedded with human neonatal fibroblasts and seeded with hiPSC-CMs partially reversed maladaptive LV remodeling and improved LV systolic/diastolic function in an immune-competent rat model of CHF. The fibroblasts lay down an extracellular matrix and secrete growth factors that increase myocardial blood flow. This approach provides an improved cell payload that covers a larger area of the damaged left ventricle as opposed to direct cell injections into the heart or down the coronary arteries. These studies combined with ongoing studies in immune-competent Yucatan mini swine treated with the same xenograft led to the preliminary design of a proposed Phase I clinical trial that will be presented to the Federal Drug Administration. For the proposed Phase I clinical, this TE patch will be implanted onto the epicardial surface of non-immunosuppressed patients undergoing elective Coronary Artery Bypass Grafting with Ejection Fractions ≥ 20% and ≤ 45%. The primary endpoints will be adverse events/severe adverse events associated with placing the TE patch on the heart. While Phase I trials are primarily safety trials, this proposed trial is designed to obtain some potential efficacy endpoints to help with the design of future Phase II/III clinical trials. These endpoints include changes in LV remodeling that were seen in the pre-clinical animal models as well as including endpoints that focus on patient well-being.

Keywords

Bioengineered patch / cardiomyocyte / cell-based therapy / fibroblast / heart failure / human induced pluripotent stem cells

References

[1] Savarese G.Division of CardiologyDepartment of MedicineKarolinska InsitutetStockholmSwedenDepartment of CardiologyKarolinska University HospitalStockholmSwedenDivision of CardiologyDepartment of MedicineKarolinska InsitutetStockholmSwedenDepartment of CardiologyKarolinska University HospitalStockholmSwedenGlobal public health burden of heart failure.Card Fail Rev2017;3:7 PMCID:PMC5494150

[2] Liu YW,Yang X.Human embryonic stem cell-derived cardiomyocytes restore function in infarcted hearts of non-human primates.Nat Biotechnol2018;36:597-605 PMCID:PMC6329375

[3] Borow KM,Greenberg B.Phase 3 DREAM-HF trial of mesenchymal precursor cells in chronic heart failure.Circ Res2019;125:265-81 PMCID:PMC6688717

[4] Sun X,Qiang B.Transplanted microvessels improve pluripotent stem cell-derived cardiomyocyte engraftment and cardiac function after infarction in rats.Sci Transl Med2020;12:eaax2992

[5] Bolli R,Hare JM.Cardiovascular Cell Therapy Research Network (CCTRN)A phase II study of autologous mesenchymal stromal cells and c-kit positive cardiac cells, alone or in combination, in patients with ischaemic heart failure: the CCTRN CONCERT-HF trial.Eur J Heart Fail2021;23:661-74 PMCID:PMC8357352

[6] Leor J,Cohen S.Cells, scaffolds, and molecules for myocardial tissue engineering.Pharmacol Ther2005;105:151-63

[7] Thai HM,Lancaster J.Implantation of a three-dimensional fibroblast matrix improves left ventricular function and blood flow after acute myocardial infarction.Cell Transplant2009;18:283-95 PMCID:PMC2739416

[8] Lancaster J,Hagerty T.Viable fibroblast matrix patch induces angiogenesis and increases myocardial blood flow in heart failure after myocardial infarction.Tissue Eng Part A2010;16:3065-73

[9] Lancaster JJ,Arnce SA.An electrically coupled tissue-engineered cardiomyocyte scaffold improves cardiac function in rats with chronic heart failure.J Heart Lung Transplant2014;33:438-45 PMCID:PMC3966928

[10] Gao L,Jung JP.Myocardial tissue engineering with cells derived from human-induced pluripotent stem cells and a native-like, high-resolution, 3-dimensionally printed scaffold.Circ Res2017;120:1318-25 PMCID:PMC5392171

[11] Wnorowski A.3-dimensionally printed, native-like scaffolds for myocardial tissue engineering.Circ Res2017;120:1224-6 PMCID:PMC5409836

[12] Menasché P,Hagège A.Transplantation of human embryonic stem cell-derived cardiovascular progenitors for severe ischemic left ventricular dysfunction.J Am Coll Cardiol2018;71:429-38

[13] Kawamura M,Miki K.Feasibility, safety, and therapeutic efficacy of human induced pluripotent stem cell-derived cardiomyocyte sheets in a porcine ischemic cardiomyopathy model.Circulation2012;126:S29-37

[14] Takahashi K.Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors.Cell2006;126:663-76

[15] Gaballa MA,Thai H,Ewy G.Grafting an acellular 3-dimensional collagen scaffold onto a non-transmural infarcted myocardium induces neo-angiogenesis and reduces cardiac remodeling.J Heart Lung Transplant2006;25:946-54

[16] Lancaster JJ,Repetti GG.Human induced pluripotent stem cell-derived cardiomyocyte patch in rats with heart failure.Ann Thorac Surg2019;108:1169-77

[17] Sanchez P,Weigand K,Goldman S.Doppler assessment of diastolic function reflect the severity of injury in rats with chronic Heart failure.J Card Fail2017;23:753-61

[18] Chinyere IR,Uhlorn J.Epicardially placed bioengineered cardiomyocyte xenograft in immune-competent rat model of heart failure.Stem Cells Int2021;2021:9935679 PMCID:PMC8325579

[19] Lancaster JJ,Chinyere IR,Fox KA.Surgical treatment for heart failure: cell-based therapy with engineered tissue.Vessel Plus2019;3:34 PMCID:PMC7418896

[20] Menasché P.Skeletal myoblasts as a therapeutic agent.Prog Cardiovasc Dis2007;50:7-17

[21] Rajagopalan P,Berthiaume F,Toner M.Polyelectrolyte nano-scaffolds for the design of layered cellular architectures.Tissue Eng2006;12:1553-63

[22] Ceccaldi C,Alfarano C.Evaluation of polyelectrolyte complex-based scaffolds for mesenchymal stem cell therapy in cardiac ischemia treatment.Acta Biomater2014;10:901-11

[23] Bushkalova R,Tenailleau C.Alginate-chitosan PEC scaffolds: a useful tool for soft tissues cell therapy.Int J Pharm2019;571:118692

[24] Morris C,Acharya T Johnson KJ.Free-breathing gradient recalled echo-based CMR in a swine heart failure model.Sci Rep2022;12:3698 PMCID:PMC8904633

[25] Soukup CR,Chan-Tram C,Sun BC.Rate of Incomplete revascularization following coronary artery bypass grafting at a single institution between 2007 and 2017.Am J Cardiol2021;144:33-6

[26] Pfeffer JM,Braunwald E.Influence of chronic captopril therapy on the infarcted left ventricle of the rat.Circ Res1985;57:84-95

[27] Yusuf S,Davis CE,Cohn JN.SOLVD InvestigatorsEffect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure.N Engl J Med1991;325:293-302

[28] Pfeffer MA,Moyé LA.Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators.N Engl J Med1992;327:669-77

[29] Mann DL. Use of ejection fraction in heart failure: a tarnished gold standard? Journal of the American College of Cardiology - ACCEL Audio Journal 2019. Available from: https://www.acc.org/Education-and-Meetings/Products-and-Resources/ACCEL-Audio [Last accessed on 20 Apr 2022]

[30] Kerkhof PL.Characterizing heart failure in the ventricular volume domain.Clin Med Insights Cardiol2015;9:11-31 PMCID:PMC4345934

[31] Gaasch WH.Left ventricular structural remodeling in health and disease: with special emphasis on volume, mass, and geometry.J Am Coll Cardiol2011;58:1733-40

[32] Cao J.The epicardium as a hub for heart regeneration.Nat Rev Cardiol2018;15:631-47 PMCID:PMC6143401

[33] Wei K,Hurtado C.Epicardial FSTL1 reconstitution regenerates the adult mammalian heart.Nature2015;525:479-85 PMCID:PMC4762253

[34] Tyser RCV,McDole K.Characterization of a common progenitor pool of the epicardium and myocardium.Science2021;371:eabb2986

[35] Vagnozzi RJ,Sargent MA.An acute immune response underlies the benefit of cardiac stem cell therapy.Nature2020;577:405-9 PMCID:PMC6962570

[36] Epstein JA,Feldman AM.Teasing the immune system to repair the heart.N Engl J Med2020;382:1660-2

[37] Vagnozzi RJ,Sargent MA.Cardiac cell therapy fails to rejuvenate the chronically scarred rodent heart.Circulation2021;144:328-31 PMCID:PMC8323965

[38] Cardiovascular Research. Cardiovascular research discoveries. Available from: https://academic.oup.com/cardiovascres/pages/webinars [Last accessed on 20 Apr 2022] Eshenhagen T, Vagnozzi R. Cardiovascular Research Discoveries. Available from: https://www.youtube.com/watch?v=yEEwx5xIqHs [Last accessed on 20 Apr 2022]

[39] Cooke JP.Inflammation and its role in regeneration and repair.Circ Res2019;124:1166-8 PMCID:PMC6578588

[40] Finan A.Stimulating endogenous cardiac repair.Front Cell Dev Biol2015;3:57 PMCID:PMC4586501